Search results for " Cardiology"

showing 10 items of 242 documents

Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation

2017

SummaryExisting clinical scores do not perform well in predicting bleeding in elderly patients with acute venous thromboembolism (VTE). We sought to derive an easy-to-use clinical score to help physicians identify elderly patients with VTE who are at high-risk of bleeding during extended anticoagulation (>3 months). Our derivation sample included 743 patients aged ≥65 years with VTE who were enrolled in a prospective multicenter cohort study. All patients received extended anticoagulation with vitamin K antagonists. We derived our score using competing risk regression, with the time to a first major bleeding up to 36 months of extended anticoagulation as the outcome, and 17 candidate var…

medicine.medical_specialtyAnemia2720 Hematology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciencesAnticoagulation0302 clinical medicineElderlyInternal medicineAnticoagulation; Bleeding risk; Elderly; HematologyBleeding riskmedicineDerivation030212 general & internal medicineInternal validation610 Medicine & healthddc:616Framingham Risk Scorebusiness.industry10031 Clinic for AngiologyCancerHematologymedicine.diseaseSurgery10209 Clinic for CardiologybusinessVenous thromboembolismMajor bleeding360 Social problems & social servicesCohort study
researchProduct

Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insight…

2020

Background: The benefits and risks of blood transfusion in patients with acute myocardial infarction who are anemic or who experience bleeding are debated. We sought to study the association between blood transfusion and ischemic outcomes according to haemoglobin nadir and bleeding status in patients with NST-elevation myocardial infarction (NSTEMI).Methods: The TAO trial randomized patients with NSTEMI and coronary angiogram scheduled within 72h to heparin plus eptifibatide versus otamixaban. After exclusion of patients who underwent coronary artery bypass surgery, patients were categorized according to transfusion status considering transfusion as a timevarying covariate. The primary isch…

medicine.medical_specialtyBlood transfusionAnemiamedicine.medical_treatmentpercutaneous coronary intervention.EptifibatideHemorrhage610 Medicine & healthpercurancous coronary intervention030204 cardiovascular system & hematologyOtamixaban11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.invention03 medical and health sciencesCoronary artery bypass surgerychemistry.chemical_compoundPercutaneous Coronary Intervention0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeNon ST elevation Myocardial Infarction[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybusiness.industryBlood transfusionPercutaneous coronary interventionAnemiamedicine.disease3. Good healthTreatment OutcomechemistryEptifibatideCardiology and Cardiovascular Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

2021

Abstract Aims  Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. Methods and results  The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to eith…

medicine.medical_specialtyCardiac & Cardiovascular SystemsINHIBITIONRATIONALEPlaceboHYPERKALEMIAMECHANISMSHyperkalaemiaChronic kidney diseaseInternal medicineDiabetes mellitusType 2 diabetes mellitusEND-POINTSPost-hoc analysismedicineHumansCanagliflozinRenal Insufficiency Chronic1102 Cardiorespiratory Medicine and HaematologySodium-Glucose Transporter 2 InhibitorsCanagliflozinOUTCOMESScience & Technologybusiness.industryType 2 Diabetes Mellitus1103 Clinical Sciencesmedicine.diseaseCardiovascular System & HematologyDiabetes Mellitus Type 2Serum potassiumCardiovascular System & CardiologyPotassiumCardiology and Cardiovascular MedicinebusinessComplicationLife Sciences & BiomedicineSGLT2 inhibitorsKidney diseasemedicine.drugEuropean Heart Journal
researchProduct

Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee o…

2020

The aims of this paper were to provide an overview of available activity monitors used in research in patients with heart failure and to identify the key criteria in the selection of the most appropriate activity monitor for collecting, reporting, and analysing physical activity in heart failure research. This study was conducted in three parts. First, the literature was systematically reviewed to identify physical activity concepts and activity monitors used in heart failure research. Second, an additional scoping literature search for validation of these activity monitors was conducted. Third, the most appropriate criteria in the selection of activity monitors were identified. Nine activi…

medicine.medical_specialtyCardiologyPhysical activity610 Medicine & healthHeart failureFitness Trackers030204 cardiovascular system & hematologyMedical and Health Sciences2705 Cardiology and Cardiovascular MedicineExercise Capacity03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitation[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansCardiac and Cardiovascular SystemsIn patientExercise physiologyAssociation (psychology)Set (psychology)ExerciseMonitoring PhysiologicHeart FailureKardiologiPhysical activitybusiness.industryPhysical activity; Activity monitor; Motion sensor; Accelerometer; Heart failuremedicine.diseaseActivity monitor[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAccelerometerHeart failure10209 Clinic for CardiologyMotion sensorPosition paperPosition PaperHuman medicineClinical MedicineCardiology and Cardiovascular MedicineRaw databusinessEuropean Journal of Heart Failure
researchProduct

18F-FDG PET/CT in cardiovascular infection and inflammation.

2021

The diagnosis of cardiovascular infection and inflammation by [18F]FDG PET/CT in Nuclear Cardiology is of growing interest, because with respect to echocardiography this technique has improved the certainty in the diagnosis of infective endocarditis in patients with prosthetic valves, the increasing number of patients with implantable cardiac devices because of the progressive ageing of the population, as well as in patients with suspected large vessel vasculitis. All are serious clinical situations which require correct diagnosis and appropriate treatment as soon as possible, because they can cause severe complications, high mortality and also increased health care costs. We review the use…

medicine.medical_specialtyCardiovascular infectionPET/CTPopulationInflammationLarge vessel vasculitismedicineeducationGeneral Environmental ScienceProsthetic valvePET-CTeducation.field_of_studyModalitiesLarge vessel vasculitis18F FDGCardiac implantable devicebusiness.industryGeneral EngineeringNuclear cardiologyProsthetic valvesmedicine.diseaseInfective endocarditisGeneral Earth and Planetary SciencesRadiologymedicine.symptomInfective endocarditisbusiness
researchProduct

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.

2009

Abstract Objective : Subjects with rheumatoid arthritis (RA) have increased cardiovascular risk and may show atherogenic forms of dyslipidemia. The present study investigated whether patients with early RA, beyond alterations in plasma lipids, also show lower LDL size and altered LDL subclass distribution. Design and Methods We identified 25 subjects with RA (47±8 years, body mass index (BMI) 25±4kg/m 2 ) by the American College of Rheumatology diagnostic criteria, with a disease durations Results As compared to controls RA patients had higher plasma triglycerides (1.8±0.5 vs. 1.0±0.5mmol/L, p p =0.0027), while total- and LDL-cholesterol concentrations were similar. LDL particle size was lo…

medicine.medical_specialtyCholesterolbusiness.industry10265 Clinic for Endocrinology and DiabetologyArthritisBlood lipids610 Medicine & healthRheumatoid arthritis small dense LDL HDL-cholesterol Triglyceridesmedicine.disease2705 Cardiology and Cardiovascular MedicineRheumatologychemistry.chemical_compoundHigh-density lipoproteinEndocrinologychemistryInternal medicineRheumatoid arthritisLow-density lipoproteinmedicineCardiology and Cardiovascular MedicinebusinessaterosclerosiDyslipidemia
researchProduct

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

2015

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

medicine.medical_specialtyConsensusStatinEpidemiologymedicine.drug_classHypercholesterolemia610 Medicine & healthComorbidity030204 cardiovascular system & hematologyRisk Assessment2705 Cardiology and Cardiovascular MedicinePatient care03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors540 ChemistrymedicineHumans030212 general & internal medicineIntensive care medicine10038 Institute of Clinical Chemistrybusiness.industryCholesterolTreat to targetCholesterol LDLGuidelineStatin treatmentTreatment OutcomechemistryCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Disease preventionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkers2713 EpidemiologyEuropean Journal of Preventive Cardiology
researchProduct

Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.

2012

Patients with obstructive sleep apnea (OSA) have proatherogenic dyslipidemia. We analyzed predictors of low-density lipoproteins' (LDLs) size in patients with OSA. In a cross-sectional study including 58 participants with OSA (30 without the metabolic syndrome [MetS] and 28 with MetS), we evaluated the size of LDL by gradient gel electrophoresis. Compared with patients without the MetS, those with MetS showed lower LDL size ( P = .007), due to a reduction in large LDL-I particles ( P = .002) and an increase in small, dense LDL-IIIA ( P = .048) and LDL-IIIB ( P = .037). The size of LDL correlated inversely with age ( r = −.268, P = .042) and serum triglycerides ( r = −.364, P = .005), and p…

medicine.medical_specialtyCross-sectional studyPolysomnography10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPolysomnography2705 Cardiology and Cardiovascular MedicineInternal medicinemedicineLow densityobstructive sleep apnea metabolic syndrome low-density lipoprotein size small dense low-density lipoprotein atherosclerosisHumansIn patientDyslipidemiasMetabolic SyndromeSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industrySleep apneamedicine.diseaseLipoproteins LDLObstructive sleep apneaCross-Sectional StudiesEndocrinologyLinear Modelslipids (amino acids peptides and proteins)Metabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemia
researchProduct

Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: cardiovascular magnetic resonance and nuclear cardiology

2016

Chemotherapy-induced cardiotoxicity (CTX) is a determining factor for the quality of life and mortality of patients administered potentially cardiotoxic drugs and in long-term cancer survivors. Therefore, prevention and early detection of CTX are highly desirable, as is the exploration of alternative therapeutic strategies and/or the proposal of potentially cardioprotective treatments. In recent years, cardiovascular imaging has acquired a pivotal role in this setting. Although echocardiography remains the diagnostic method most used to monitor cancer patients, the need for more reliable, reproducible and accurate detection of early chemotherapy-induced CTX has encouraged the introduction o…

medicine.medical_specialtyDiagnostic methodspositron emission tomographycardiotoxicityEarly detectionAntineoplastic Agents030204 cardiovascular system & hematologynuclear cardiologyVentricular Function Left030218 nuclear medicine & medical imagingAntineoplastic Agent03 medical and health sciencescardiovascular magnetic resonance0302 clinical medicineQuality of lifeNeoplasmsInternal medicineEarly DiagnosimedicineHumanscardiotoxicity; cardiovascular magnetic resonanceCardiotoxicitymedicine.diagnostic_testbusiness.industryMyocardiumcardiotoxicity; cardiovascular magnetic resonance; nuclear cardiology; positron emission tomography; Antineoplastic Agents; Cardiotoxicity; Echocardiography; Humans; Neoplasms; Quality of Life; Early Diagnosis; Magnetic Resonance Imaging; Positron-Emission TomographyCancerMagnetic resonance imagingGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingOxygenEarly DiagnosisCardiovascular DiseasesPositron emission tomographyEchocardiographyPositron-Emission TomographyCardiologyQuality of Lifecardiotoxicity cardiovascular magnetic resonance nuclear cardiology positron emission tomographyNeoplasmCardiology and Cardiovascular MedicineCardiac magnetic resonancebusinessHuman
researchProduct

Recommendations of the Geriatric Cardiology Section of the Spanish Society of Cardiology for the Assessment of Frailty in Elderly Patients With Heart…

2018

Frailty is an age-associated clinical syndrome characterized by a decrease in physiological reserve in situations of stress, constituting a state of vulnerability that involves a higher risk of adverse events. Its prevalence in Spain is high, especially in elderly individuals with comorbidity and chronic diseases. In cardiovascular disease, frailty is associated worse clinical outcomes and higher morbidity and mortality in all scenarios, in both acute and chronic settings, and could consequently influence diagnosis and treatment. However, frailty is often not addressed or included when planning the management of elderly patients with heart disease. In this article, we review the available s…

medicine.medical_specialtyHeart DiseasesHeart diseaseGerontologíaFrail ElderlyEnfermedad cardiovascularCardiologyVulnerabilityGuidelines as TopicContext (language use)Cardiología geriátricaDisease030204 cardiovascular system & hematologyScientific evidence03 medical and health sciencesGeriatric cardiology0302 clinical medicinemedicineValoración geriátricaHumansAdverse effectIntensive care medicineGeriatric AssessmentAged 80 and overFrailtybusiness.industryGeneral Medicinemedicine.diseaseComorbidityGeriatricsSpainMorbiditybusinessRevista Española de Cardiología (English Edition)
researchProduct